CAR T-CELL THERAPY AS A TREATMENT OPTION FOR BLOOD CANCER PATIENTS

The following videos were recorded at the Leukemia & Lymphoma Society’s 2019 CAR T Conference in New York City on June 28, 2019. If you wish to apply for credit for your participation, please enroll and complete the course requirements. Your comments are important to us. Even if you do not wish to apply for credit, we would appreciate your feedback which will help us improve future programs. Once you are done with the videos, please complete the evaluation. Scroll down to the bottom of the page for the link.

Group 1

  • Welcome and Overview – David L. Porter, MD (Chair) and Lauren Berger, MPH
  • LLS Impact – Gwen L. Nichols, MD
  • CAR T-cell Clinical Applications: Is it Right for My Patients? – Sergio A. Giralt, MD
  • CAR T Toxicity and Management – Ran Reshef, MD, MSc
  • CAR T-cells for ALL – Jamie L. Koprivnikar, MD

Group 2

  • CAR T-cells: A Major Advance for Patients with Refractory DLBCL – Ira Braunschweig, MD
  • It Takes a Village: Panel Presentations & Discussion – Heather DiFilippo, MSN, CRNP, Nigina Mirazimova, MSN, RN, OCN®,Mari Lynne Silverberg, MPA, RN, BSN, OCN® and Elizabeth A. Weber, BSN, RN

Group 3

  • CAR T-cells for CLL – Jacqueline C. Barrientos, MD, MS and Joanna M. Rhodes, MD
  • Case Presentations: NHL and Myeloma: Referral, Tx and Follow up – Koen van Besien, MD, PhD and Deepu Madduri, MD

Group 4

  • CAR T-cells for Myeloma: The Next Major Disease Target? – Adam D. Cohen, MD
  • CAR T cells, Jump-starting your program – Dennis L. Cooper, MD
  • Q & A – Dennis L. Cooper, MD
  • Value, Cost & Reimbursement for CAR T cells: Overcoming the Obstacles – Gunjan L. Shah, MD